Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17133142 | PROCESS OF TRANSFECTING PRIMORDIAL GERM CELLS IN AN AVIAN | December 2020 | October 2024 | Allow | 46 | 3 | 0 | Yes | No |
| 17131564 | GENE THERAPY FOR JUVENILE BATTEN DISEASE | December 2020 | January 2025 | Allow | 49 | 4 | 0 | Yes | No |
| 17125368 | METHOD FOR PREPARING ALZHEIMER'S DISEASE (AD) ANIMAL MODEL | December 2020 | April 2024 | Abandon | 40 | 2 | 0 | Yes | No |
| 17110868 | GENETICALLY MODIFIED MOUSE THAT EXPRESSES HUMANIZED PD1 AND PD-L1 PROTEINS | December 2020 | May 2024 | Allow | 41 | 2 | 1 | No | No |
| 17055003 | PRODUCTS FOR THERAPY OF A MUSCULOSKELETAL CONDITION AND METHODS FOR THEIR PRODUCTION | November 2020 | April 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17070276 | GENETICALLY MODIFIED CHICKEN WITH AN INACTIVATED OVOMUCOID GENE | October 2020 | June 2024 | Abandon | 44 | 3 | 0 | Yes | No |
| 16976720 | CONJUGATES COMPRISING AAVs AND CAS9 POLYPEPTIDES | August 2020 | April 2025 | Allow | 56 | 4 | 1 | Yes | No |
| 16975422 | NUCLEOTIDE SEQUENCES ENCODING PEPTIDE LINKERS | August 2020 | February 2024 | Abandon | 42 | 0 | 1 | No | No |
| 16970350 | PLASMID ENCODING A C-TERMINAL FRAGMENT OF PARASPECKLE COMPONENT 1 FOR TREATING TUMORS | August 2020 | December 2024 | Allow | 52 | 2 | 1 | Yes | No |
| 16939871 | Universal Human Induced Pluripotent Stem Cells And Method Of Forming The Same | July 2020 | April 2024 | Abandon | 45 | 3 | 1 | No | No |
| 16938661 | CRISPR-RELATED METHODS AND COMPOSITIONS | July 2020 | April 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16961195 | TRANSGENIC RAINBOW SHARK | July 2020 | March 2024 | Allow | 45 | 4 | 1 | Yes | No |
| 16956798 | PLACENTA-DERIVED CELL-CONDITIONED MEDIUM FOR INDUCING DEDIFFERENTIATION INTO INDUCED PLURIPOTENT STEM CELLS FROM SOMATIC CELLS AND METHOD FOR INDUCING DEDIFFERENTIATION USING THE SAME | June 2020 | March 2024 | Abandon | 44 | 3 | 1 | Yes | No |
| 16771541 | GENETICALLY MODIFIED RAT THAT EXPRESSES AN F54L TXN1 MUTANT | June 2020 | December 2023 | Allow | 42 | 3 | 0 | Yes | No |
| 16759352 | PROCESS FOR CONTINUOUS CELL CULTURE OF GPSCS | April 2020 | October 2024 | Abandon | 54 | 2 | 1 | Yes | No |
| 16842309 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | April 2020 | July 2024 | Allow | 51 | 4 | 1 | Yes | No |
| 16835144 | HIGHLY FUNCTIONAL MANUFACTURED STEM CELLS | March 2020 | November 2024 | Abandon | 56 | 4 | 1 | No | No |
| 16651862 | FISH AND METHOD FOR PRODUCING FISH | March 2020 | February 2024 | Abandon | 47 | 4 | 0 | Yes | No |
| 16816826 | LOSS OF FUNCTION RODENT MODEL OF SOLUTE CARRIER 39 MEMBER 5 | March 2020 | March 2025 | Abandon | 60 | 3 | 0 | Yes | Yes |
| 16778558 | METHOD OF ENHANCING VIRAL-MEDIATED GENE DELIVERY | January 2020 | April 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16625999 | TRANSGENIC MOUSE MODEL OF NEUROFIBROMATOSIS TYPE 1 | December 2019 | March 2024 | Allow | 51 | 3 | 1 | Yes | No |
| 16612675 | MEASURING FREQUENCY OF VARIOUS SUBSETS OF PATHOGEN-SPECIFIC T CELLS IN PERIPHERAL BLOOD AS ESTABLISHED BY VARIOUS PATTERNS OF TCR-INDUCED CA2+ SIGNALING | November 2019 | May 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16607074 | METHOD FOR GENERATING A GENETICALLY MODIFIED PIG WITH INACTIVATED PORCINE ENDOGENOUS RETROVIRUS (PERV) ELEMENTS | October 2019 | September 2023 | Allow | 47 | 3 | 0 | No | No |
| 16600117 | AGENT FOR ACCELERATING MATURATION OR AGING OF CELLS | October 2019 | October 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16499636 | TRANSGENIC RAINBOW SHARK | September 2019 | June 2024 | Abandon | 56 | 2 | 1 | No | Yes |
| 16530452 | TRANSGENIC C57BL6-BTBR MOUSE WITH A HUMANIZED MHC II GENE THAT EXPRESSES GAD65 | August 2019 | March 2024 | Allow | 55 | 4 | 1 | Yes | No |
| 16476891 | METHOD OF TRANSDIFFERENTIATING HAIR FOLLICLE STEM CELLS INTO SPERM STEM CELLS | July 2019 | October 2024 | Allow | 60 | 8 | 0 | Yes | No |
| 16361873 | TRANSGENIC MICE WITH HUMANIZED MHC I AND IMMUNOGLOBLUIN HEAVY CHAIN GENES | March 2019 | March 2025 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 16203004 | GUIDE RNA THAT TARGETS A MUTANT HUMAN GUANYLATE CYCLASE 2A ALLELE | November 2018 | August 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16203056 | GUIDE RNA THAT TARGETS A MUTANT HUMAN INOSINE MONOPHOSPHATE DEYHYDROGENASE I ALLELE | November 2018 | December 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16197164 | SELF-INACTIVATING LENTIVIRAL VECTOR ENCODING BETA- OR GAMMA-GLOBIN | November 2018 | June 2024 | Abandon | 60 | 5 | 1 | Yes | Yes |
| 16195054 | IMPROVED METHOD OF MAKING INDUCED PLURIPOTENT STEM CELLS USING P53 INHIBITORS | November 2018 | February 2024 | Allow | 60 | 6 | 2 | Yes | No |
| 16082157 | METHOD OF INACTIVATING A FEL D1 GENE USING CRISPR | September 2018 | March 2024 | Allow | 60 | 7 | 1 | Yes | Yes |
| 16070769 | TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON | July 2018 | December 2023 | Allow | 60 | 7 | 1 | Yes | No |
| 15818710 | GUIDE RIBONUCLEIC ACID SEQUENCES THAT TARGET THE HUMAN CCR5 GENE | November 2017 | March 2025 | Abandon | 60 | 9 | 0 | No | Yes |
| 15785530 | DUCK EMBRYONIC DERIVED STEM CELL LINES FOR THE PRODUCTION OF VIRAL VACCINES | October 2017 | April 2024 | Abandon | 60 | 4 | 0 | No | Yes |
| 15587254 | METHODS OF GENERATING RETINAL PROGENITOR CELL PREPARATIONS AND USES THEREOF | May 2017 | June 2024 | Abandon | 60 | 8 | 1 | Yes | Yes |
| 15516731 | METHOD FOR GENERATING T-CELL PROGENITORS | April 2017 | April 2024 | Allow | 60 | 8 | 1 | Yes | Yes |
| 15308116 | MOUSE MODEL OF HYPERURICEMIA | November 2016 | March 2019 | Allow | 28 | 2 | 1 | Yes | No |
| 15127295 | A TRANSGENE CONSTRUCT ENCODING DELTA 12 FATTY ACID | September 2016 | September 2018 | Allow | 24 | 1 | 1 | No | No |
| 14873708 | Recombinant Influenza Viruses for Vaccines and Gene Therapy | October 2015 | October 2016 | Allow | 12 | 0 | 0 | No | No |
| 14733514 | PLURIPOTENT CELLS DERIVED FROM BONE MARROW AND METHODS FOR ISOLATION | June 2015 | January 2017 | Abandon | 20 | 7 | 0 | Yes | Yes |
| 14388220 | AN RNA VECTOR WITH AN OPEN READING FRAME, AN ALBUMIN 3' UTR, AND A HISTONE STEM LOOP | September 2014 | September 2017 | Allow | 36 | 2 | 1 | No | No |
| 14328888 | Mito-Ob: A Transgenic Mouse Model for Obesity | July 2014 | July 2017 | Allow | 36 | 3 | 1 | No | No |
| 14236945 | RBAP48 TRANSGENIC MICE FOR DRUG DISCOVERY IN AGE-RELATED MEMORY DECLINE | June 2014 | March 2016 | Allow | 25 | 0 | 1 | No | No |
| 14295004 | METHODS AND COMPOSITIONS FOR PRODUCING INDUCED AIRWAY TISSUE PROGENITOR CELLS | June 2014 | November 2017 | Allow | 42 | 4 | 1 | Yes | No |
| 14359850 | GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING sST2 FOR THE TREATMENT OF AIRWAY IMMUNE INFLAMMATORY AND LUNG DISEASE | May 2014 | January 2016 | Allow | 20 | 1 | 0 | No | No |
| 14157915 | REASSORTANT INFLUENZA VIRUSES FOR VACCINES | January 2014 | June 2015 | Allow | 16 | 1 | 0 | No | No |
| 13775314 | IMMORTALIZED AVIAN CELL LINES AND USE THEREOF | February 2013 | May 2014 | Allow | 14 | 0 | 0 | No | No |
| 13394481 | CELLS AND METHODS FOR OBTAINING THEM | August 2012 | November 2014 | Abandon | 32 | 1 | 1 | No | No |
| 13538995 | Method for Producing Dendritic Cells | June 2012 | August 2014 | Allow | 26 | 2 | 1 | No | No |
| 13501998 | Induction of Germ Cells from Pluripotent Cells | May 2012 | November 2017 | Allow | 60 | 2 | 1 | No | Yes |
| 13471501 | EXPRESSION VECTOR AND METHODS OF PRODUCING HIGH LEVELS OF PROTEINS | May 2012 | October 2015 | Allow | 41 | 2 | 0 | No | No |
| 13434805 | TRANSGENIC MICE EXPRESSING HUMAN TOLL-LIKE RECEPTOR 8 | March 2012 | December 2014 | Allow | 32 | 1 | 0 | No | No |
| 13393103 | METHOD OF SELECTING SAFE PLURIPOTENT STEM CELLS | March 2012 | June 2014 | Allow | 28 | 1 | 0 | No | No |
| 13375099 | METHOD FOR SELECTING CLONE OF INDUCED PLURIPOTENT STEM CELLS | January 2012 | December 2014 | Allow | 37 | 2 | 0 | Yes | No |
| 13265626 | A METHOD OF MAKING MACROPHAGE EXPRESSING AN ANTIBODY DIRECTED AGAINST BETA-AMYLOID | January 2012 | June 2013 | Allow | 20 | 1 | 1 | No | No |
| 13331314 | Recombinant Influenza Viruses for Vaccines and Gene Therapy | December 2011 | January 2015 | Allow | 36 | 3 | 0 | No | Yes |
| 13324856 | A METHOD OF IDENTIFYING TUMOR ASSOCIATED ANTIGENS | December 2011 | September 2015 | Allow | 45 | 2 | 1 | No | Yes |
| 13206056 | AVIAN CELL LINES | August 2011 | June 2024 | Abandon | 60 | 10 | 0 | No | Yes |
| 13179281 | A NUCLEIC ACID CONSTRUCT HAVING AN OVALBUMIN PROMOTER | July 2011 | October 2012 | Allow | 15 | 0 | 1 | No | No |
| 13106080 | A METHOD OF MAKING RECOMBINANT INFLUENZA VIRUS | May 2011 | July 2014 | Allow | 38 | 1 | 1 | Yes | No |
| 13051508 | METHODS OF TREATING HYPERTENSION | March 2011 | April 2012 | Allow | 13 | 2 | 0 | Yes | No |
| 13023757 | REDUCTION OF DERMAL SCARRING | February 2011 | August 2012 | Allow | 18 | 2 | 0 | No | No |
| 12986868 | SUSTAINED CULTURE OF AVIAN GONOCYTES | January 2011 | August 2014 | Allow | 44 | 2 | 1 | No | Yes |
| 12679570 | KNOCKOUT MICE FOR A P450 GENE CLUSTER | September 2010 | April 2014 | Allow | 49 | 3 | 1 | Yes | No |
| 12855383 | TRANSGENIC ANIMALS FOR ANALYZING CYP3A4 CYTOCHROME P450 GENE REGULATION | August 2010 | August 2013 | Allow | 36 | 2 | 1 | Yes | No |
| 12823243 | ANIMAL MODEL FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CYSTIC FIBROSIS | June 2010 | September 2014 | Allow | 51 | 2 | 1 | Yes | No |
| 12602723 | A KNOCKIN MOUSE WITH A DISRUPTION IN A PXR GENE EXPRESSING HUMAN PXR | June 2010 | July 2013 | Allow | 44 | 2 | 2 | No | No |
| 12791577 | METHODS OF TREATMENT USING A VECTOR ENCODING P21/CIP1 | June 2010 | November 2013 | Allow | 41 | 4 | 1 | Yes | No |
| 12777731 | IMMORTALIZED AVIAN CELL LINES AND USE THEREOF | May 2010 | January 2013 | Allow | 32 | 1 | 1 | No | No |
| 12451019 | STEM CELL LINES FROM DEER ANTLERS, THEIR APPLICATION AND CULTURE METHODS | February 2010 | March 2012 | Allow | 29 | 1 | 0 | No | No |
| 11922548 | EXPRESSION VECTOR AND METHODS OF PRODUCING HIGH LEVELS OF PROTEINS | January 2010 | July 2015 | Allow | 60 | 4 | 1 | Yes | No |
| 12532548 | A METHOD OF DETERMINING CHICKEN EMBRYONIC STEM CELLS | September 2009 | February 2012 | Allow | 29 | 2 | 1 | Yes | No |
| 12524268 | A MOUSE MODEL FOR EYE DISEASE | July 2009 | June 2012 | Allow | 35 | 2 | 1 | No | No |
| 12378304 | IN VIVO TRANSFECTION IN AVIANS | February 2009 | June 2010 | Allow | 16 | 2 | 0 | Yes | No |
| 12353463 | MOUSE CARRYING A KNOCK-OUT MUTATION OF THE QPCT-GENE | January 2009 | June 2016 | Allow | 60 | 4 | 1 | No | Yes |
| 12313064 | METHODS OF PROTEIN PRODUCTION USING OVOMUCOID PROMOTERS | November 2008 | May 2010 | Allow | 18 | 2 | 0 | Yes | No |
| 12298221 | A TRANSGENIC MOUSE MODEL OF B CELL MALIGNANCY | November 2008 | November 2009 | Allow | 13 | 0 | 0 | No | No |
| 12209321 | TRANSGENIC MOUSE MODELS OF AB OVEREXPRESSION | September 2008 | June 2012 | Allow | 45 | 2 | 2 | Yes | No |
| 12219298 | METHODS FOR MAKING DEFINITIVE ENDODERM HEPATOCYTE (DE-HEP) PROGENITOR CELLS | July 2008 | September 2014 | Allow | 60 | 5 | 1 | Yes | No |
| 12088640 | SASPASE KNOCKOUT ANIMAL | June 2008 | July 2010 | Allow | 27 | 1 | 0 | No | No |
| 12151841 | System for and method of introducing additives to biological materials using supercritical fluids | May 2008 | September 2014 | Allow | 60 | 4 | 1 | Yes | Yes |
| 11660878 | TRANSGENIC MOUSE MODELS OF HEPATITIS C VIRUS (HCV) AND IDENTIFICATION OF HVC THERAPEUTICS | May 2008 | May 2009 | Allow | 26 | 0 | 0 | No | No |
| 12110972 | MDR1 VARIANTS AND METHODS FOR THEIR USE | April 2008 | April 2010 | Allow | 24 | 1 | 0 | Yes | No |
| 12098037 | PROPAGATION AND/OR DERIVATION OF EMBRYONIC STEM CELLS | April 2008 | May 2009 | Allow | 13 | 1 | 0 | No | No |
| 12075992 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISORDERS | March 2008 | January 2011 | Allow | 34 | 1 | 1 | No | No |
| 12012387 | METHODS OF PROTEIN PRODUCTION IN CELL LINES | February 2008 | June 2008 | Allow | 4 | 0 | 0 | No | No |
| 12021078 | COMPOSITIONS AND METHODS FOR AMELIORATING MYOSIN VIIA DEFECTS | January 2008 | March 2010 | Allow | 25 | 2 | 0 | No | No |
| 12010426 | Method for Transforming a Hair Follicle | January 2008 | May 2014 | Allow | 60 | 8 | 0 | Yes | Yes |
| 11996003 | TRANSGENIC NON-HUMAN ANIMAL MODEL OF LUNG TUMORIGENESIS | January 2008 | May 2009 | Allow | 16 | 1 | 0 | No | No |
| 11986671 | TRANSGENIC MOUSE WHOSE GENOME COMPRISES A HOMOZYGOUS DISRUPTION OF ITS ALPHA1G GENE, A METHOD OF PREPARING THE SAME AND USE THEREOF | November 2007 | July 2009 | Allow | 20 | 1 | 0 | No | No |
| 11975760 | DESMIN GENE HAVING NOVEL POINT MUTATION CAUSATIVE OF DILATED CARDIOMYOPATHY | October 2007 | August 2010 | Allow | 33 | 2 | 1 | Yes | No |
| 11902018 | HUMAN SALIVARY GLAND-ORIGIN STEM CELL | September 2007 | September 2009 | Allow | 24 | 1 | 0 | No | No |
| 11841648 | NON-HUMAN ORGANISM COMPRISING A GENE EXPRESSION MODULATION SYSTEM ENCODING A CHIMERIC RETINOID X RECEPTOR | August 2007 | July 2013 | Allow | 60 | 6 | 1 | Yes | Yes |
| 11842406 | MOUSE MODEL OF CHOLINERGIC DYSFUNCTION TO EVALUATE COGNITIVE ENHANCERS AND DRUGS THAT IMPROVE MYASTHENIA | August 2007 | May 2015 | Allow | 60 | 6 | 0 | Yes | Yes |
| 11841526 | PULLULANASE VARIANTS WITH INCREASED PRODUCTIVITY | August 2007 | November 2010 | Allow | 39 | 2 | 1 | Yes | Yes |
| 11841597 | METHOD OF MODULATING GENE EXPRESSION USING AN ECDYSONE RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | August 2007 | July 2011 | Allow | 47 | 4 | 1 | No | No |
| 11832165 | ISOLATION, SELECTION AND PROPAGATION OF ANIMAL TRANSGENIC STEM CELLS | August 2007 | August 2008 | Allow | 13 | 1 | 0 | No | No |
| 11815014 | DIABETES MODEL ANIMAL | July 2007 | September 2009 | Allow | 26 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WILSON, MICHAEL C.
With a 45.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WILSON, MICHAEL C works in Art Unit 1638 and has examined 147 patent applications in our dataset. With an allowance rate of 84.4%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 44 months.
Examiner WILSON, MICHAEL C's allowance rate of 84.4% places them in the 61% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by WILSON, MICHAEL C receive 2.88 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WILSON, MICHAEL C is 44 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -5.0% benefit to allowance rate for applications examined by WILSON, MICHAEL C. This interview benefit is in the 6% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 19.3% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 42.7% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 53% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 71.1% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 48.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 90.7% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 18.4% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.6% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.